The programmed cell death protein 1 (PD-1) receptor, or its ligand 1 (PD-L1) directed agents became crucial in the treatment of NSCLC including atezolizumab (ATEZO), nivolumab (NIVO), and pembrolizumab (PEMBRO) [4,8]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.